Marina, on Track with FAP Drug, Starts Looking to Raise Needed Cash

With less than a quarter's worth of funds, the company's is banking on a public stock and warrant offering that could gross as much as $13.8 million.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories